+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 1Year - 39Years
All Genders
ID07013565

A Phase 2 Study of Risk-Adapted Chemoimmunotherapy Using Nivolumab, Vinblastine, and Brentuximab Vedotin for Children and Young Adults with Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

Led by New York Medical College · Updated on 2026-05-20

20

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

This trial focuses on children, adolescents, and young adults with relapsed or refractory high-risk ALK-positive Anaplastic Large Cell Lymphoma ALCL, a condition with low overall survival rates. Researchers are studying whether combining the FDA-approved immunotherapy drug Nivolumab NIVO with chemotherapy, tailored to the patients risk status, can improve treatment response and survival. The study also evaluates the use of allogeneic stem cell transplantation stem cells from another person following this combined therapy to further improve outcomes in this high-risk group. Participants are assigned to different treatment groups based on their risk level. Low-risk patients receive Vinblastine alone for induction and possibly extended therapy if remission is achieved. High-risk patients without prior exposure to Brentuximab vedotin BV receive a combination of BV and NIVO for induction, followed by stem cell transplant if remission is reached. High-risk patients previously treated with BV receive Vinblastine plus NIVO initially, with possible addition of BV based on response. Treatment cycles are typically given every 21 days, and therapy is adjusted according to disease response. During the study, participants will undergo disease assessments after induction cycles to evaluate treatment response. Researchers will monitor safety by tracking adverse events related to the drugs used. They will measure overall response rates and event-free survival over one year. The study includes regular performance status evaluations and organ function assessments. Participants may receive stem cell transplantation as part of their treatment plan. The total participation duration includes induction therapy, consolidation, and follow-up assessments to monitor safety and effectiveness over time.

CONDITIONS

Brief Title

Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

Research Team

M

Mitchell S Cairo, MD

L

Lauren Harrison, RN, MSN

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here